Sana Biotechnology to Present Preclinical Data on Novel In Vivo CAR-T Therapy SG293 at ASGCT 2026
核心洞察
Sana Biotechnology will present preclinical data on SG293 (搜索), a CD19 (搜索)-directed in vivo CAR-T product candidate, at the ASGCT 2026 Annual Meeting in Boston.
SG293 (搜索) uses proprietary fusogen-based delivery technology to specifically target CD8 (搜索)+ T cells while avoiding off-target delivery to organs like the liver.
The therapy represents a differentiated approach for both oncology and autoimmune indications, potentially addressing key safety concerns with current CAR-T therapies.
Sana Biotechnology announced that preclinical data from its innovative in vivo CAR-T therapy SG293 (搜索) has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, scheduled for May 11-15, 2026 in Boston, Massachusetts.
Novel In Vivo CAR-T Approach
SG293 (搜索) represents a CD19 (搜索)-directed in vivo CAR-T product candidate that utilizes Sana's proprietary fusogen-based delivery technology. The therapy is designed as a CD8 (搜索)-targeted fusosome that delivers genetic material specifically to CD8+ T cells to generate CD19-directed CAR-T cells in vivo, while avoiding potentially problematic delivery to tissues such as the liver.
The presentation, titled "Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293 (搜索)," will be delivered on Tuesday, May 12, 2026, from 8:15-8:30 a.m. ET during the session "Advancing in vivo gene delivery with non-AAV viral vector systems" at MCEC Room 257AB.
Technology Platform and Mechanism
The fusogen technology underlying SG293 (搜索) is engineered to enable cell-specific delivery of genetic material that integrates into the DNA of target cells. This approach aims to address key off-target concerns associated with current CAR-T therapies by providing precise cellular targeting capabilities.
According to the company's description, SG293 (搜索) represents a differentiated approach for enabling potent and precise in vivo CAR-T therapy that could potentially benefit both oncology and autoimmune treatment paradigms.
Therapeutic Applications
Sana Biotechnology intends to explore SG293 (搜索) across multiple therapeutic areas, including B-cell cancers (搜索) and B-cell mediated autoimmune diseases (搜索). This dual application potential reflects the versatility of the CD19 (搜索)-targeting approach, which has shown efficacy in treating various B-cell malignancies and is being investigated for autoimmune conditions where B-cells play a pathogenic role.
Company Background
Sana Biotechnology focuses on creating and delivering engineered cells as medicines for patients, with operations in Seattle, Washington, Cambridge, Massachusetts, and South San Francisco, California. The company's mission centers on repairing and controlling genes, replacing missing or damaged cells, and making therapies broadly available to patients.